Ultragenyx Pharmaceutical (RARE) Gross Profit (2018 - 2026)

Ultragenyx Pharmaceutical (RARE) has 9 years of Gross Profit data on file, last reported at $106.0 million in Q1 2026.

• Quarterly Gross Profit fell 3.64% year-over-year to $106.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $559.4 million (up 11.49% YoY) and the FY2025 annual result came in at $564.0 million, up 16.77% from the prior year.
• Gross Profit declined to $106.0 million in Q1 2026 per RARE's latest filing, from $177.9 million in the prior quarter.
• Across five years, Gross Profit topped out at $177.9 million in Q4 2025 and bottomed at $73.8 million in Q1 2022.
• The 5-year median for Gross Profit is $106.0 million (2026), against an average of $110.4 million.
• The widest annual swing landed in 2022, when Gross Profit declined 21.62%; it then soared 36.07% in 2024.
• Tracing RARE's Gross Profit over 5 years: stood at $98.0 million in 2022, then climbed by 17.62% to $115.3 million in 2023, then rose by 27.91% to $147.5 million in 2024, then increased by 20.65% to $177.9 million in 2025, then sank by 40.43% to $106.0 million in 2026.
• Per Business Quant, the three latest RARE Gross Profit figures stand at $106.0 million (Q1 2026), $177.9 million (Q4 2025), and $131.9 million (Q3 2025).

Peer Comparison